Skip to main content
Top

02-19-2016 | Hyperglycemic hyperosmolar state | Review | Article

Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia

Authors: Guillermo Umpierrez, Mary Korytkowski

share
SHARE

Abstract

Diabetic ketoacidosis (DKA), hyperglycaemic hyperosmolar state (HHS) and hypoglycaemia are serious complications of diabetes mellitus that require prompt recognition, diagnosis and treatment. DKA and HHS are characterized by insulinopaenia and severe hyperglycaemia; clinically, these two conditions differ only by the degree of dehydration and the severity of metabolic acidosis. The overall mortality recorded among children and adults with DKA is <1%. Mortality among patients with HHS is ~10-fold higher than that associated with DKA. The prognosis and outcome of patients with DKA or HHS are determined by the severity of dehydration, the presence of comorbidities and age >60 years. The estimated annual cost of hospital treatment for patients experiencing hyperglycaemic crises in the USA exceeds US$2 billion. Hypoglycaemia is a frequent and serious adverse effect of antidiabetic therapy that is associated with both immediate and delayed adverse clinical outcomes, as well as increased economic costs. Inpatients who develop hypoglycaemia are likely to experience a long duration of hospital stay and increased mortality. This Review describes the clinical presentation, precipitating causes, diagnosis and acute management of these diabetic emergencies, including a discussion of practical strategies for their prevention.

Nat Rev Endocrinol 2016; 12: 222–232. doi: 10.1038/nrendo.2016.15

Key points
  • Diabetic ketoacidosis (DKA) and hyperglycaemic hyperosmolar state (HHS) are serious acute metabolic complications of diabetes mellitus, representing points along a spectrum of hyperglycaemic emergencies caused by poor glycaemic control
  • DKA comprises hyperglycaemia, hyperketonaemia and metabolic acidosis; diagnostic criteria for HHS include a plasma glucose level >33.3 mmol/l, serum osmolality >320 mmol/kg and no appreciable metabolic acidosis and ketonaemia
  • Management objectives for DKA and HHS include restoration of circulatory volume and tissue perfusion; correction of hyperglycaemia, ketogenesis and electrolyte imbalance; and identification and treatment of the precipitating event
  • Hypoglycaemia is defined as a blood glucose level <3.9 mmol/l in both the inpatient and outpatient settings
  • Severe hypoglycaemic events can negate the beneficial effects of intensive glycaemic management strategies that target near normoglycaemia among patients with diabetes mellitus
  • Patient and family education regarding the signs and symptoms of hypoglycaemia, as well as the methods available for treatment, can effectively reduce the risk of severe hypoglycaemic episodes

Diabetic ketoacidosis (DKA), hyperglycaemic hyperosmolar state (HHS) and hypoglycaemia are frequent and serious complications arising among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). In the USA, ~145,000 cases of DKA occur each year1, 2. The rate of hospitalization for HHS is lower, accounting for <1% of all diabetes- related admissions3, 4. The frequency of emergency room visits for hypoglycaemia is similar to that reported for severe hyperglycaemia1, 5. Among hospitalized individuals, hypoglycaemia is a frequent complication of ongoing treatment for hyperglycaemia, with a reported incidence of 5–28% in intensive care unit (ICU) trials (depending on the intensity of glycaemic control)6, and 1–33% in non-ICU trials using subcutaneous insulin therapy7, 8.

Literature
  1. Kitabchi, A. E., Umpierrez, G. E., Miles, J. M. & Fisher, J. N. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32, 1335–1343 (2009).
  2. Centers for Disease Control and Prevention. Diabetes data & trends. [online], (2015).
  3. Fishbein, H. A. & Palumbo, P. J. in Diabetes in America 2nd edn Ch. 13 283–291 (National Institutes of Health, 1995).
  4. Pasquel, F. J. & Umpierrez, G. E. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care 37, 3124–3131 (2014).
  5. Geller, A. I. et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Int. Med. 174, 678–686 (2014).
  6. Krikorian, A., Ismail-Beigi, F. & Moghissi, E. S. Comparisons of different insulin infusion protocols: a review of recent literature. Curr. Opin. Clin. Nutr. Metab. Care 13, 198–204 (2010).
  7. Umpierrez, G. E. et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 30, 2181–2186 (2007).
  8. Umpierrez, E. et al. Randomized study of basal bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 34, 256–261 (2011).
  9. Basu, A. et al. Persisting mortality in diabetic ketoacidosis. Diabet. Med. 10, 282–284 (1993).
  10. Malone, M. L., Gennis, V. & Goodwin, J. S. Characteristics of diabetic ketoacidosis in older versus younger adults. J. Am. Geriatr. Soc. 40, 1100–1104 (1992).
  11. Bhowmick, S. K., Levens, K. L. & Rettig, K. R. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr. Pract. 11, 23–29 (2005).
  12. Fadini, G. P. et al. Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. Diabetes Res. Clin. Pract. 94, 172–179 (2011).
  13. McCoy, R. G. et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35, 1897–1901 (2012).
  14. Kitabchi, A. E. et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 24, 131–153 (2001).
  15. Umpierrez, G. E., Kelly, J. P., Navarrete, J. E., Casals, M. M. & Kitabchi, A. E. Hyperglycemic crises in urban blacks. Arch. Intern. Med. 157, 669–675 (1997).
  16. Boucai, L., Southern, W. N. & Zonszein, J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am. J. Med. 124, 1028–1035 (2011).
  17. Kosiborod, M. et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 301, 1556–1564 (2009).
  18. Garg, R., Hurwitz, S., Turchin, A. & Trivedi, A. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients. Diabetes Care 36, 1107–1110 (2013).
  19. Finfer, S. et al. Hypoglycemia and risk of death in critically ill patients. N. Engl. J. Med. 367, 1108–1118 (2012).
  20. Carey, M., Boucai, L. & Zonszein, J. Impact of hypoglycemia in hospitalized patients. Curr. Diabetes Rep. 13, 107–113 (2013).
  21. Rhoads, G. G. et al. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J. Occup. Environ. Med. 47, 447–452 (2005).
  22. Turchin, A. et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 32, 1153–1157 (2009).
  23. Randall, L. et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 34, 1891–1896 (2011).
  24. Taylor, S. I., Blau, J. E. & Rother, K. I. SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015).
  25. Peters, A. L. et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38, 1687–1693 (2015).
  26. Ennis, E. D., Stahl, E. J. & Kreisberg, R. A. The hyperosmolar hyperglycemic syndrome. Diabetes Rev. 2, 115–126 (1994).
  27. Foster, D. W. & McGarry, J. D. The metabolic derangements and treatment of diabetic ketoacidosis. N. Engl. J. Med. 309, 159–169 (1983).
  28. McGarry, J. D. & Foster, D. W. Regulation of hepatic fatty acid oxidation and ketone body production. Ann. Rev. Biochem. 49, 395–420 (1980).
  29. McGarry, J. D., Woeltje, K. F., Kuwajima, M. & Foster, D. W. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab. Rev. 5, 271–284 (1989).
  30. Reichard, G. A. Jr, Skutches, C. L., Hoeldtke, R. D. & Owen, O. E. Acetone metabolism in humans during diabetic ketoacidosis. Diabetes 35, 668–674 (1986).
  31. Gerich, J. E., Martin, M. M. & Recant, L. Clinical and metabolic characteristics of hyperosmolar nonketotic coma. Diabetes 20, 228–238 (1971).
  32. Umpierrez, G. & Freire, A. X. Abdominal pain in patients with hyperglycemic crises. J. Crit. Care 17, 63–67 (2002).
  33. Guo, R. X., Yang, L. Z., Li, L. X. & Zhao, X. P. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case–control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J. Obstet. Gynaecol. Res. 34, 324–330 (2008).
  34. Stephens, J. M., Sulway, M. J. & Watkins, P. J. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes 20, 485–489 (1971).
  35. Sheikh-Ali, M. et al. Can serum β-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care 31, 643–647 (2008).
  36. Taboulet, P. et al. Urinary acetoacetate or capillary β-hydroxybutyrate for the diagnosis of ketoacidosis in the emergency department setting. Eur. J. Emerg. Med. 11, 251–258 (2004).
  37. Arieff, A. I. & Kleeman, C. R. Cerebral edema in diabetic comas. II. Effects of hyperosmolality, hyperglycemia and insulin in diabetic rabbits. J. Clin. Endocrinol. Metab. 38, 1057–1067 (1974).
  38. Luzi, L., Barrett, E. J., Groop, L. C., Ferrannini, E. & DeFronzo, R. A. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 37, 1470–1477 (1988).
  39. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Hyperglycemic emergencies in adults. Can. J. Diabetes 37, S72–S76 (2013).
  40. Goyal, N., Miller, J. B., Sankey, S. S. & Mossallam, U. Utility of initial bolus insulin in the treatment of diabetic ketoacidosis. J. Emerg. Med. 38, 422–427 (2010).
  41. Kitabchi, A. E., Ayyagari, V. & Guerra, S. M. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann. Intern. Med. 84, 633–638 (1976).
  42. Umpierrez, G. E. et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 32, 1164–1169 (2009).
  43. Umpierrez, G. E. et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am. J. Med. 117, 291–296 (2004).
  44. Ersoz, H. O. et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int. J. Clin. Pract. 60, 429–433 (2006).
  45. Karoli, R., Fatima, J., Salman, T., Sandhu, S. & Shankar, R. Managing diabetic ketoacidosis in non-intensive care unit setting: role of insulin analogs. Indian J. Pharmacol. 43, 398–401 (2011).
  46. Umpierrez, G. E. et al. Subcutanbeous aspart insulin: a safe and cost effective treatment of diabetic ketoacidosis. Diabetes 52 (Suppl. 1), 584A (2003).
  47. Sobngwi, E. et al. Evaluation of a simple management protocol for hyperglycaemic crises using intramuscular insulin in a resource-limited setting. Diabetes Metab. 35, 404–409 (2009).
  48. Adrogue, H. J., Lederer, E. D., Suki, W. N. & Eknoyan, G. Determinants of plasma potassium levels in diabetic ketoacidosis. Med. (Baltimore) 65, 163–172 (1986).
  49. Chua, H. R., Schneider, A. & Bellomo, R. Bicarbonate in diabetic ketoacidosis — a systematic review. Ann. Intensive Care 1, 23 (2011).
  50. Fisher, J. N. & Kitabchi, A. E. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J. Clin. Endocrinol. Metab. 57, 177–180 (1983).
  51. Wilson, H. K., Keuer, S. P., Lea, A. S. & Boyd, A. E. 3rd & Eknoyan, G. Phosphate therapy in diabetic ketoacidosis. Arch. Intern. Med. 142, 517–520 (1982).
  52. Winter, R. J., Harris, C. J., Phillips, L. S. & Green, O. C. Diabetic ketoacidosis: induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am. J. Med. 67, 897–900 (1979).
  53. White, N. H. Diabetic ketoacidosis in children. Endocrinol. Metab. Clin. North Am. 29, 657–682 (2000).
  54. Savage, M. W. et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet. Med. 28, 508–515 (2011).
  55. Hsia, E. et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J. Clin. Endocrinol. Metab. 97, 3132–3137 (2012).
  56. Jefferies, C. A. et al. Preventing diabetic ketoacidosis. Pediatr. Clin. North Am. 62, 857–871 (2012).
  57. Vanelli, M. et al. Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care 22, 7–9 (1999).
  58. Laffel, L. Sick-day management in type 1 diabetes. Endocrinol. Metab. Clin. North Am. 29, 707–723 (2000).
  59. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [online], (2015).
  60. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. Risk of diabetic ketoacidosis to be examined. [online], (2015).
  61. Erondu, N., Desai, M., Ways, K. & Meininger, G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38, 1680–1686 (2015).
  62. Cryer, P. E. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 63, 2188–2195 (2014).
  63. Cryer, P. Hypoglycemia during therapy of diabetes. Endotext.org [online], (2015).
  64. Cryer, P. E. Hypoglycemia-associated autonomic failure in diabetes: maladaptive, adaptive, or both? Diabetes 64, 2322–2323 (2015).
  65. Weinstock, R. S. et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J. Clin. Endocrinol. Metab. 98, 3411–3419 (2013).
  66. Miller, C. D. et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 161, 1653–1659 (2001).
  67. McCoy, R. G. et al. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr. Pract. 19, 792–799 (2013).
  68. Wexler, D. J., Meigs, J. B., Cagliero, E., Nathan, D. M. & Grant, R. W. Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 30, 367–369 (2007).
  69. Umpierrez, G. E. et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 36, 2169–2174 (2013).
  70. Lleva, R. R., Thomas, P., Bozzo, J. E., Hendrickson, K. C. & Inzucchi, S. E. Using the glucometrics website to benchmark ICU glucose control before and after the NICE-SUGAR study. J. Diabetes Sci. Technol. 8, 918–922 (2014).
  71. Leese, G. P. et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26, 1176–1180 (2003).
  72. Kerry, C., Mitchell, S., Sharma, S., Scott, A. & Rayman, G. Diurnal temporal patterns of hypoglycaemia in hospitalized people with diabetes may reveal potentially correctable factors. Diabet. Med. 30, 1403–1406 (2013).
  73. Seaquist, E. R. et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J. Clin. Endocrinol. Metab. 98, 1845–1859 (2013).
  74. Seaquist, E. R. et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36, 1384–1395 (2013).
  75. Cryer, P. E., Davis, S. N. & Shamoon, H. Hypoglycemia in diabetes. Diabetes Care 26, 1902–1912 (2003).
  76. Moghissi, E. S. et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr. Pract. 15, 353–369 (2009).
  77. Moghissi, E. S. et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32, 1119–1131 (2009).
  78. Umpierrez, G. E. et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 16–38 (2012).
  79. Hsu, P. F. et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 36, 894–900 (2013).
  80. Chow, E. et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 63, 1738–1747 (2014).
  81. Goto, A., Arah, O. A., Goto, M., Terauchi, Y. & Noda, M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347, f4533 (2013).
  82. Reno, C. M. et al. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes 62, 3570–3581 (2013).
  83. Tsujimoto, T. et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care 37, 217–225 (2014).
  84. Tanenberg, R. J., Newton, C. A. & Drake, A. J. Confirmation of hypoglycemia in the 'dead-in-bed' syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr. Pract. 16, 244–248 (2010).
  85. Razavi Nematollahi, L. et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism 58, 443–448 (2009).
  86. Seaquist, E. R. et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 35, 409–414 (2012).
  87. The Accord Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364, 818–828 (2011).
  88. Miller, M. E. et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340, b5444 (2010).
  89. Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169 (2011).
  90. Zoungas, S. et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410–1418 (2010).
  91. Fox, C. S. et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38, 1777–1803 (2015).
  92. Gill, G. V., Woodward, A., Casson, I. F. & Weston, P. J. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes — the 'dead in bed' syndrome revisited. Diabetologia 52, 42–45 (2009).
  93. Desouza, C. V., Bolli, G. B. & Fonseca, V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33, 1389–1394 (2010).
  94. Amiel, S. A., Dixon, T., Mann, R. & Jameson, K. Hypoglycaemia in type 2 diabetes. Diabet. Med. 25, 245–254 (2008).
  95. Feinkohl, I. et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 37, 507–515 (2014).
  96. DiNardo, M., Noschese, M., Korytkowski, M. & Freeman, S. The medical emergency team and rapid response system: finding, treating, and preventing hypoglycemia. Jt. Comm. J. Qual. Patient Saf. 32, 591–595 (2006).
  97. Korytkowski, M., DiNardo, M., Donihi, A. C., Bigi, L. & Devita, M. Evolution of a diabetes inpatient safety committee. Endocr. Pract. 12 (Suppl. 3), 91–99 (2006).
  98. Umpierrez, G. E. et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 16–38 (2012).
  99. Maynard, G., Lee, J., Phillips, G., Fink, E. & Renvall, M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm. J. Hosp. Med. 4, 3–15 (2009).
  100. Noschese, M. et al. Effect of a diabetes order set on glycaemic management and control in the hospital. Qual. Saf. Health Care 17, 464–468 (2008).
  101. Korytkowski, M., McDonnell, M. E., Umpierrez, G. E. & Zonszein, J. Patient guide to managing hyperglycemia (high blood sugar) in the hospital. J. Clin. Endocrinol. Metab. 97, 27A–28A (2012).
  102. Moore, C. & Woollard, M. Dextrose 10% or 50% in the treatment of hypoglycaemia out of hospital? A randomised controlled trial. Emerg. Med. J. 22, 512–515 (2005).
  103. Graveling, A. J. & Frier, B. M. Risks of marathon running and hypoglycaemia in type 1 diabetes. Diabet. Med. 27, 585–588 (2010).
  104. Schabelman, E. & Kuo, D. Glucose before thiamine for Wernicke encephalopathy: a literature review. J. Emerg. Med. 42, 488–494 (2012).
  105. Deusenberry, C. M., Coley, K. C., Korytkowski, M. T. & Donihi, A. C. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 32, 613–617 (2012).
  106. Fleseriu, M., Skugor, M., Chinnappa, P. & Siraj, E. S. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr. Pract. 12, 635–640 (2006).
  107. Korytkowski, M. T. Diabetes and aging. Diabetes Spectrum. 26, 3–4 (2013).
  108. Little, S. A. et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 37, 2114–2122 (2014).
  109. Samann, A., Muhlhauser, I., Bender, R., Kloos, C. & Muller, U. A. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 48, 1965–1970 (2005).
  110. Bott, S., Bott, U., Berger, M. & Muhlhauser, I. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 40, 926–932 (1997).
  111. Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S. & Amiel, S. A. Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care 38, 1592–1609 (2015).
  112. Tylee, T. & Hirsch, I. B. Costs associated with using different insulin preparations. JAMA 314, 665–666 (2015).
  113. Bergenstal, R. M., Welsh, J. B. & Shin, J. J. Threshold insulin-pump interruption to reduce hypoglycemia. N. Engl. J. Med. 369, 1474 (2013).
  114. Baldwin, D. et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 35, 1970–1974 (2012).
  115. Thuzar, M., Malabu, U. H., Tisdell, B. & Sangla, K. S. Use of a standardised diabetic ketoacidosis management protocol improved clinical outcomes. Diabetes Res. Clin. Pract. 104, e8–e11 (2014).
  116. Weinert, L. S. et al. Precipitating factors of diabetic ketoacidosis at a public hospital in a middle-income country. Diabetes Res. Clin. Pract. 96, 29–34 (2012).
  117. Tan, H., Zhou, Y. & Yu, Y. Characteristics of diabetic ketoacidosis in Chinese adults and adolescents — a teaching hospital-based analysis. Diabetes Res. Clin. Pract. 97, 306–312 (2012).
  118. Suwarto, S., Sutrisna, B., Waspadji, S. & Pohan, H. T. Predictors of five days mortality in diabetic ketoacidosis patients: a prospective cohort study. Acta Med. Indones. 46, 18–23 (2014).
  119. Ko, S. H. et al. Clinical characteristics of diabetic ketoacidosis in Korea over the past two decades. Diabet. Med. 22, 466–469 (2005).
  120. Edo, A. E. Clinical profile and outcomes of adult patients with hyperglycemic emergencies managed at a tertiary care hospital in Nigeria. Niger. Med. J. 53, 121–125 (2012).
  121. Guisado-Vasco, P. et al. Clinical features, mortality, hospital admission, and length of stay of a cohort of adult patients with diabetic ketoacidosis attending the emergency room of a tertiary hospital in Spain. Endocrinol. Nutr. 62, 277–284 (2015).
  122. Alourfi, Z. & Homsi, H. Precipitating factors, outcomes, and recurrence of diabetic ketoacidosis at a university hospital in Damascus. Avicenna J. Med. 5, 11–15 (2015).
  123. Lin, S. F., Lin, J. D. & Huang, Y. Y. Diabetic ketoacidosis: comparisons of patient characteristics, clinical presentations and outcomes today and 20 years ago. Chang Gung Med. J. 28, 24–30 (2005).